{"groups":[{"description":"Minocycline 100 mg (capsule) two times a day to begin with start of maintenance therapy (3 months +/- 2 days)","id":"FG000","title":"Minocycline"},{"description":"Placebo 100 mg (capsule) two times a day to begin with start of maintenance therapy (3 months +/- 2 days)","id":"FG001","title":"Placebo"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"6"},{"groupId":"FG001","numSubjects":"4"}],"type":"Withdrawal by Subject"},{"reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"2"}],"type":"Adverse Event"},{"reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"0"}],"type":"Too ill to continue"},{"reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"1"}],"type":"Switched chemo"},{"reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"0"}],"type":"Lack of compliance"},{"reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"1"}],"type":"Requested to be removed from the study"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"43"},{"groupId":"FG001","numSubjects":"44"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"33"},{"groupId":"FG001","numSubjects":"36"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"10"},{"groupId":"FG001","numSubjects":"8"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"preAssignmentDetails":"88 participants enrolled and randomized to either the intervention group or the control group. 1 patient withdrew before the study began.","recruitmentDetails":"All recruitment done at the University of Texas MD Anderson Cancer"}